The Summit Forum on Oncolytic Virus Innovative Drug Research Successfully Concluded, Clinical Research and Results Transformation Future

Nearly 500 people from the field of oncolysis, including experts, researchers, entrepreneurs, representatives of R & D enterprises, practitioners of service institutions and media representatives, gathered together to discuss the research of innovative oncolytic virus drugs and promote clinical research and achievement transformation.

The main forum was presided over by Guo Jun, deputy director of Beijing Cancer Research Institute, director of melanoma and sarcoma Department of internal medicine and urology of Beijing Cancer Hospital, vice chairman and Secretary General of CSCO, and chairman of CSCO melanoma special committee. Cheng Shujun, academician of the Chinese Academy of Engineering and researcher of the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, Huang Yunhong, reviewer of the Clinical Department of Biological Products of the Drug Review Center of the State Drug Administration, Professor appointed by the President of Peking Union Medical College of the Chinese Academy of Medical Sciences, expert in oncology, expert in clinical research of anti-tumor drugs, chairman of the China Cancer Foundation and president of the Xiongan New District Medical Association, Shi Yuankan District, H.I Andtbacka,MD, Surgery, university of Utah School of Medicine, Phasse III,Robert, T-VEC of Key PI, Deputy Director of Department of Oncology, Cancer Hospital of Chinese Academy of Medical Sciences, Postdoctoral Doctor of NCI, Deputy Director of Colorectal Oncology Committee of Beijing Oncology Society, Deputy Director and Secretary General of Esophageal Cancer Expert Committee of CSCO Huang Jing, Co-founder and Chief Scientist of Stardust Biology Lu Jinhua, Professor Deng Liang of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, liu Binlei, chairman and general manager of Wuhan Binhui Biotechnology Co., Ltd., and other guests attended the opening ceremony and delivered a report. Song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association, attended the opening ceremony and delivered a speech.

On behalf of the organizers, President Song Ruilin expressed warm congratulations on the convening of this forum, heartfelt thanks to the guests for their arrival, and thanks to Wuhan Binhui Biotechnology Co., Ltd. for its strong support. He said that oncolytic viruses have aroused great attention from the oncology community, medical research community, and innovation community. Experts in various fields have devoted a lot of effort to the journey of cancer prevention and treatment in China. Today, many experts gather to discuss oncolytic viruses. The research will leave a strong mark for the development of China's medical innovation!

Academician Cheng Shujun brought a report on the theme of "Aging and Tumor-Survival with Tumor. Studies have shown that tumor is not a local lesion, but a systemic disease closely related to the aging process. Host factors (personal lifestyle) play an important role in the occurrence and development of tumor. He proposed that survival with tumors is an important research direction, turning advanced metastatic cancer into chronic disease treatment, and cancer prevention and treatment strategies should be patient-centered. He advocated the goal of delaying aging and preventing tumors through scientific nutrition (and lifestyle), reasonable exercise, good mentality, and livable living environment (nature and society).

Professor Huang Yunhong shared the oncolytic virus drugs and their characteristics, the drafting process and main contents of the guiding principles to the guests and the audience on the "guiding principles for the design of clinical trials of oncolytic virus drugs. She gave a detailed description of the key points and risk control of clinical trial design in conjunction with the Guiding Principles for Clinical Trial Design of Oncolytic Viruses (Trial) issued by the Drug Review Center of the State Food and Drug Administration on February 9, 2021. She stressed the need to strengthen communication in the approval process. Due to the limited review time, the researchers and the reviewers communicate in advance from the perspective of research and development and review, which can enhance the understanding of both parties and facilitate the smooth follow-up declaration and research and development path.

Professor Shi Yuankai gave a keynote report entitled "The History and Prospect of Innovative Drug Research and Development in China. He pointed out that in 2020, there were about 4.569 million new cases of malignant tumors and about 3.003 million deaths in China. Both new cases and deaths ranked first in the world. There is still much room for improvement in the 5-year survival rate of Chinese lung cancer patients. Through the 60-year history of anti-tumor drugs in China and the 16-year review of lung cancer research and development, we can see that the results of clinical trials have rewritten Chinese clinical practice guidelines. At the same time, a large number of innovative drugs into the national health insurance drug list, 2018-2022, a total of 87 anti-tumor drugs into the national health insurance drug list, benefiting patients. It is foreseeable that new targets and new mechanisms of anti-tumor drugs will be the future research direction.

Professor Deng Liang made a report on "Innovating non-replicating vaccinia virus to activate innate and adaptive anti-tumor immunity. She gives a brief introduction to poxviruses and explains the rationale for using the non-replicating modified vaccinia virus Ankara as a viral platform, as well as the mechanisms of action of the first generation rMVA(MQ710) and the second generation rMVA(MQ833). Deng Liang said that the product/drug development is currently in the early stages, and she will further bring the two generations of MQ701 and MQ833 to the market in China and the United States.

Professor Robert gave a keynote speech on "The impact of the clinical development of T-VEC on the future of oncolytic virus treatment. He pointed out that China is a pioneer in innovative research on oncolytic viruses. In 2005 and 2006, Oncorine H101 was approved for the first time in China. Seven years ago, both the EMA and the FDA approved the T-VEC. HSV-1-derived oncolytic cell immunotherapy designed to produce local and systemic antitumor effects. Robert said that T-VEC paves the way for oncolytic virus immunotherapy, and the future of oncolytic virus immunotherapy is bright.

At the forum, experts discussed the theme of "innovation and cooperation-promoting the research and development of oncolytic virus drugs. The theme discussion was presided over by Professor Guo Jun, with the participation of Professor Huang Jing, Dr. Lu Jinhua, Professor Robert and Dr. Liu Binlei. The guests conducted in-depth discussions on the current situation, innovation points and prospects of oncolytic virus drug research and development, providing new perspectives and new viewpoints for the participants.

The Oncolytic Virus Innovative Drug Research Summit Forum was successfully concluded. The successful holding of the forum will further promote the clinical research and development of oncolytic virus innovative drugs and the transformation of results. This forum lasted for one and a half days. Dozens of important guests in the industry focused on the research of innovative oncolytic virus drugs. Through the latest clinical data and research and development progress, they studied and interpreted the development trend of the industry from multiple angles, bringing a feast of knowledge to the audience.